메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achie…

SHANGHAI, Aug. 12, 2025 -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, manufacture, and commercialize XH-S004 in Chinese Mainland, Hong Kong SAR
- 김갑성 기자
- 2025-08-12 09:36
Zoomlionの社名を冠した衛星が軌道に投入され、デジタル化、知能化、グリーン化、…

[ 메디채널 김갑성 기자 ] 中国・日照、2025年8月12日 --Zoomlion Heavy Industry Science & Technology Co., Ltd.（「Zoomlion」、1157.HK）は、「Zoomlion」の社名を冠した衛星が軌道投入に成功し、世界の建設機械業界で初となる快挙を達成しました。北京時間0時31分、山東省日照市沖の沿岸海域からJielong-3搬ロケットにより、Geely Constellation Group 04衛星が打ち上げられ、そのうちの1基がZoomlionの名称を冠していました。「Zoomlion」衛星は、同社が地上の建設現場から広大な宇宙空間へと事業領域を拡大したことを象徴しています。これは、Zoomlionがデジタル化、知能化、持続可能性、そしてグローバル展開を加速し、最も厳しい環境においてもサービス提供を可能にするという決意を示しています。建設機械のイノベーションを牽引するリーダーとして、Zoomlionは、8つの国家レベル研究プラットフォーム、1万7,800件以上の特許出願、そして570件を超える業界標準を通じて進歩を推進しています。その画期的な製品には、中国初の3,000トン級クローラクレーン、世界最長の101メートル炭素繊維製ブームポンプ車、初の1万ト
- 김갑성 기자
- 2025-08-12 08:58
Sleep Health Week: Researchers Recruiting Now for CBD Inso…

During Sleep Health Week (11-15 August 2025), Australians living with insomnia are reminded that a new treatment is on the horizon – with clinical trial sites actively recruiting now. MELBOURNE, Australia, Aug. 12, 2025 -- Avecho Biotechnology Limited (Avecho) is today alerting Australians to recruitment efforts for the largest ever clinical trial ('the Trial') for the treatment of insomnia with a pharmaceutical cannabidiol (CBD) product – with clinical trial sites now live across the country. The Trial is a placebo-controlled study assessing the use of CBD for insomnia, recruit
- 김갑성 기자
- 2025-08-12 08:32
Lockheed Martin Announces New Industrial Collaboration P…

Lockheed Martin and Southern Methodist University to drive digital innovation, intellectual property creation, and workforce development in partnership with Philippine universities MANILA, Philippines, Aug. 12, 2025 -- Lockheed Martin is expanding its industrial collaboration package for the Philippines as part of its F-16 Block 70 solution for the country's Multi Role Fighter program. The enhanced offer includes a strategic partnership with Southern Methodist University (SMU) to drive digital innovation, intellectual property creation, and workforce development with Philippine
- 김갑성 기자
- 2025-08-12 08:00
Intas & Accord signs Agreement to acquire Prothya Biosolut…

AHMEDABAD, India, Aug. 11, 2025 -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly. This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global pre
- 김갑성 기자
- 2025-08-11 21:41
AGEBOX Presents iKids-Growth: Pioneering Safe and Natural S…

RICHMOND, VA., Aug. 11, 2025 -- In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aids—from basic multivitamins to protein powders—with little more than hope to guide them. iKids-Growth marks a meaningful step forward, moving beyond passive nutritional support and toward a more proactive, biologically-informed strategy. AGEBOX, a trailblazer in pediatric health, is responding to the growing parental demand for safe, hormone-free height support—with iKids-Growth, the first-ever supple
- 김갑성 기자
- 2025-08-11 21:30
Caliber Enters 25th Year of Empowering Global Pharma with GxP…

HYDERABAD, India, Aug. 11, 2025 -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences industry, proudly announces the start of its 25th year of operations. With over two decades of expertise, Caliber has helped pharmaceutical and biotechnology companies in 17 countries enhance quality systems, streamline operations, and ensure regulatory compliance. To mark this milestone, Caliber unveiled a new anniversary logo, officially installed at the company's India headquarters in Hyderabad. "The logo brings together th
- 김갑성 기자
- 2025-08-11 21:22
EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER A…

PLANTATION, Fla., Aug. 11, 2025 -- Everise, a global leader in transforming customer experiences, today announced two senior leadership appointments as the company continues its growth trajectory and expansion in global markets. Industry veteran Robert Jimenez joins as Chief Revenue Officer (CRO), while accomplished finance leader Steven Amaya takes on the role of Chief Financial Officer (CFO). These strategic appointments come as Everise continues to expand its global footprint, scale its operations, and deepen its partnerships with some of the world's leading
- 김갑성 기자
- 2025-08-11 21:00
REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK

Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 -- Dr. Brian Kennedy, one of the world's leading Longevity researchers, gave a keynote presentation at the Nutritional Business Journal's annual CEO conference in Palos Verdes CA last week. Dr. Kennedy previewed highlights from his team's use of advanced AI driven statistics to analyze the data from a large longevity study of 4,260 health enthusiast subjects who purchased at least one saliva based DNA epigenetic test between 2020 and 2025. The subjects de
- 김갑성 기자
- 2025-08-11 20:06
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a Ne…

— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling— Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies— AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fa
- 김갑성 기자
- 2025-08-11 20:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분